< Back to latest news & events

News

EU SPC waiver for generic pharmaceuticals producers

May 2019

The awaited regulation which will introduce a “manufacturing waiver” for EU SPCs relating to medicinal products has been formally adopted by the EU Council and is expected to enter into force on 1 July 2019 (dependent on the date of publication of the Regulation in the EU’s Official Journal).

Broadly speaking, the regulation will introduce an exception to the protection granted to an original medicine by an SPC for export purposes and/or for stockpiling, provided that particular conditions are met.

Initially, the regulation will affect only SPCs that are applied for on or after the date of entry into force of the regulation. However, three years after the date of entry into force, the regulation will also affect SPCs applied for before that date, but which have become effective after that date.

In summary, the exception applies to:

  • manufacture of a product for the purposes of export to third countries (where protection of the original medicine does not exist or has expired) and to related acts which are strictly necessary for that manufacture or export; and
  • only in the last six months of validity of the SPC, manufacture of a product for the purposes of storing in the Member State of manufacture (in order to market the product in the EU after expiry of the SPC) and any related acts strictly necessary for that manufacture or storage.

The exception will only operate if certain conditions are met. For example, key requirements are that:

  • the maker (the person on whose behalf the relevant manufacture takes place) has provided certain information required by the regulation to both the authorities of the Member State of manufacture and to the SPC holder at least three months in advance of manufacture or an earlier related act;
  • the maker has duly informed others involved in the commercialisation of the product who are performing excepted acts; and
  • the maker has affixed to the packaging of the product the specific logo provided for by the regulation indicating clearly that it is only for export.

In its press release the Council said that “The regulation will remove the competitive disadvantages faced by EU-based manufacturers of generics and biosimilars vis-à-vis manufacturers established outside the EU in global markets.”

This update was prepared by Karen Russell, Senior Patent Attorney. If you have any queries about the regulation, please contact Karen. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

Fashionably IP - podcast exploring hot topics in the world of fashion and intellectual property

We are delighted to launch our new Fashionably IP Podcast were we will be looking at important hot topics in the world of fashion and intellectual property. In the podcast, …

Read article
Event - 24th June 2022

pro-manchester Trailblazing Tech Conference 2022

pro-manchester is hosting their Trailblazing Tech Conference 2022 on Friday 24th June. At this event, speakers and attendees will be discussing developments in fintech and cyber security, analysing the impact …

Event details

HGF ranked Gold in the FT special report – Europe’s Leading Patent Law Firms 2022

HGF has been ranked in the ‘Gold’ and ‘Silver’ bands in The Financial Times special report ‘Europe’s Leading Patent Law Firms’ published on the 16th June 2022. More than 10,000 …

Read article